Puma Biotechnology, Inc. has announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines...
Objective: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of neratinib in human epidermal growth factor receptor (HER2)+ breast cancer (BC).
Puma Biotechnology announced that the FDA has approved Nerlynx (neratinib), formerly known as PB272, a once-daily oral tyrosine kinase inhibitor...
Puma Biotechnology, Inc. announced top line results from the Phase III clinical trial of Puma's investigational drug PB 272 (neratinib)...
Puma Biotechnology has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for PB 272 (neratinib). The...
Puma Biotechnology, Inc. announced that the FDA has approved a labeling supplement for Nerlynx (neratinib) for the extended adjuvant treatment...
Puma Biotechnology, Inc. announced that the FDA has accepted for review the New Drug Application (NDA) for its lead product...
Pfizer has granted a worldwide licence of neratinib, its Phase-III oral tyrosine kinase inhibitor, to Puma Biotechnology. Neratinib is a...
-Puma Biotechnology, Inc.) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Puma Biotechnology, Inc. announced top line results from the Phase II clinical trial of Puma's investigational drug PB 272 (neratinib)...